OncoSec Medical (NASDAQ:ONCS) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoSec Medical (NASDAQ:ONCSGet Rating) in a research report report published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, BTIG Research lowered OncoSec Medical from a buy rating to a neutral rating in a report on Monday, November 14th.

OncoSec Medical Stock Performance

Shares of ONCS opened at $3.73 on Monday. OncoSec Medical has a 52 week low of $3.35 and a 52 week high of $34.76. The firm has a market capitalization of $6.68 million, a price-to-earnings ratio of -0.18 and a beta of 1.79. The business’s fifty day moving average price is $10.55 and its two-hundred day moving average price is $14.49.

Institutional Trading of OncoSec Medical

A hedge fund recently raised its stake in OncoSec Medical stock. Bank of New York Mellon Corp grew its position in OncoSec Medical Incorporated (NASDAQ:ONCSGet Rating) by 653.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 386,074 shares of the biotechnology company’s stock after purchasing an additional 334,849 shares during the quarter. Bank of New York Mellon Corp owned about 0.98% of OncoSec Medical worth $444,000 as of its most recent SEC filing. Institutional investors own 13.22% of the company’s stock.

OncoSec Medical Company Profile

(Get Rating)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.

Read More

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.